A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

NCT06094881 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia
Treatment

Interventions

DRUG: Obinutuzumab Injection [Gazyva]

Sponsor

Institute of Hematology & Blood Diseases Hospital, China